Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
07/04/2026 14:19
April 7 (Reuters) - Nurexone Biologic Inc NRX.V: NUREXONE BIOLOGIC’S U.S. SUBSIDIARY EXO-TOP AND FLORIDA-BASED BIOXTEK SIGN STRATEGIC LOI FOR EXOSOME MANUFACTURING AND COMMERCIALIZATION NUREXONE BIOLOGIC INC - PARTIES TO NEGOTIATE STRATEGIC PARTNERSHIP FOR GMP MANUFACTURING AND COMMERCIALIZATION OF MSC EXOSOMES NUREXONE BIOLOGIC INC - BIOXTEK MAY SUPPORT MANUFACTURING OF NAÏVE EXOSOMES FOR U.S. CLINICAL TRIALS OF EXOPTEN Source text: ID:nGNX77CZGd Further company coverage: NRX.V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement